{
    "hands_on_practices": [
        {
            "introduction": "The first step in managing a patient with colorectal liver metastases is to establish a sound overall strategy, a process that requires integrating numerous clinical variables. This practice challenges you to think like a multidisciplinary tumor board, synthesizing complex patient data into a logical decision algorithm. By formalizing the criteria for resectability, liver function, disease burden, and patient fitness, you will learn to triage patients into the most appropriate initial pathways: immediate surgery, conversion chemotherapy, or palliation .",
            "id": "5100500",
            "problem": "A surgical oncology service is developing a standardized triage pathway for patients with colorectal liver metastases. The pathway must assign patients to one of three initial strategies: immediate hepatic resection, conversion systemic chemotherapy, or palliative care. The algorithm must be grounded in core surgical oncologic principles. For this problem, use the following fundamental base and definitions:\n\n- Margin-negative resection is defined as complete removal of all visible and microscopic disease with negative margins. The surgical goal is a margin-negative resection while preserving adequate functional liver and maintaining vascular inflow, vascular outflow, and biliary drainage.\n- Future liver remnant (FLR) is the fraction of functional liver expected to remain after resection. Accepted minimal FLR thresholds in contemporary practice are $0.20$ for a normal liver, $0.30$ for a liver with chemotherapy-associated steatohepatitis or nonalcoholic steatohepatitis, and $0.40$ for cirrhosis.\n- The ability to achieve a margin-negative resection with preservation of inflow/outflow/drainage may rely on established surgical adjuncts, such as portal vein embolization (PVE), two-stage hepatectomy, or parenchymal-sparing techniques, but not on biologic tumor downsizing.\n- Limited, technically resectable extrahepatic disease (for example, a solitary pulmonary metastasis) does not preclude curative intent if it can be addressed in a staged or synchronous manner. Widespread, unresectable extrahepatic disease (for example, diffuse peritoneal carcinomatosis not amenable to cytoreduction) precludes curative hepatectomy.\n- High operative risk, such as American Society of Anesthesiologists (ASA) class $4$ with unstable cardiopulmonary disease, generally contraindicates major hepatectomy; in such patients, minor interventions may be considered only if oncologic benefit outweighs risk.\n\nDefine the following patient-level variables to formalize the decision logic:\n\n- $R \\in \\{0,1\\}$ indicates whether a margin-negative resection preserving inflow/outflow/drainage is anatomically achievable now using accepted surgical adjuncts but without relying on systemic therapy for tumor downsizing. $R=1$ means achievable, $R=0$ means not achievable.\n- $F \\in (0,1)$ denotes the predicted future liver remnant fraction.\n- $H \\in \\{0,1,2\\}$ encodes hepatic parenchymal status, with $H=0$ for normal liver, $H=1$ for steatohepatitis or chemotherapy-injured liver, and $H=2$ for cirrhosis.\n- $E \\in \\{0,1,2\\}$ encodes extrahepatic disease status, with $E=0$ for none, $E=1$ for limited and resectable, and $E=2$ for unresectable or disseminated.\n- $C \\in \\{0,1\\}$ encodes operative risk, with $C=0$ for acceptable risk and $C=1$ for prohibitive risk (for example, ASA class $4$ with decompensated failure).\n\nLet $f(H)$ denote the minimal FLR threshold required for safe resection, such that $f(0)=0.20$, $f(1)=0.30$, and $f(2)=0.40$.\n\nThree representative patients are being considered:\n\n- Patient $1$: Age $55$, bilobar colorectal liver metastases confined to the liver; two-stage hepatectomy with right portal vein embolization is planned, preserving inflow/outflow/drainage with expected $F=0.28$ in a normal liver ($H=0$); no extrahepatic disease ($E=0$); operative risk acceptable (ASA class $2$, so $C=0$). Anatomically, a margin-negative plan is feasible with established adjuncts ($R=1$).\n- Patient $2$: Age $62$, numerous bilobar metastases abutting major hepatic veins and portal bifurcation; current anatomy precludes margin-negative resection without tumor downsizing ($R=0$); predicted $F=0.22$ in a chemotherapy-injured liver ($H=1$); no extrahepatic disease ($E=0$); operative risk acceptable ($C=0$).\n- Patient $3$: Age $70$, multifocal hepatic metastases with diffuse peritoneal carcinomatosis (not amenable to complete cytoreduction) and mediastinal nodal involvement ($E=2$); comorbid severe heart failure (ASA class $4$, so $C=1$); regardless of anatomy, curative intent hepatectomy is not feasible.\n\nFour candidate algorithms are proposed. Each algorithm maps $(R,F,H,E,C)$ to one of three outputs: “Resection,” “Conversion chemotherapy,” or “Palliation.” Choose the single algorithm that most consistently adheres to the stated principles and correctly triages Patients $1$–$3$.\n\nA. If $C=1$ or $E=2$, output “Palliation.” Else, if $R=1$ and $F \\ge f(H)$, output “Resection.” Else, if $R=0$ and $E \\in \\{0,1\\}$, output “Conversion chemotherapy.” Else, output “Palliation.”\n\nB. If $E \\ge 1$, output “Palliation.” Else, if $R=1$ and $F \\ge 0.20$, output “Resection.” Else, output “Conversion chemotherapy.”\n\nC. If $R=1$, output “Resection” regardless of $F$, $H$, $E$, or $C$. Else, if $F \\ge 0.15$, output “Conversion chemotherapy.” Else, output “Palliation.”\n\nD. If disease is bilobar, output “Conversion chemotherapy” regardless of $R$, $F$, $H$, $E$, or $C$. Else, if $R=1$ and $F \\ge f(H)$ and $C=0$ and $E=0$, output “Resection.” Else, output “Palliation.”",
            "solution": "The problem statement has been validated and found to be scientifically grounded, well-posed, objective, and internally consistent. It provides a formal framework for a real-world clinical decision-making process in surgical oncology, using clearly defined variables and principles. The problem is valid and a solution can be derived.\n\nThe core principles of surgical triage for colorectal liver metastases, as stated in the problem, can be synthesized into a hierarchical decision algorithm:\n$1$. The first step is to identify absolute contraindications to curative-intent major hepatectomy. If present, the patient's pathway is palliative. Based on the problem description, these contraindications are prohibitive operative risk ($C=1$) or widespread, unresectable extrahepatic disease ($E=2$).\n$2$. If there are no absolute contraindications, the next step is to assess for immediate resectability. A patient is a candidate for \"Resection\" if and only if all of the following conditions are met:\n    a. The tumor(s) are anatomically resectable with a negative margin, preserving vital structures ($R=1$). This is achievable with standard surgical adjuncts but without requiring tumor downsizing from systemic therapy.\n    b. The future liver remnant (FLR) is sufficient for the underlying liver quality ($F \\ge f(H)$).\n    c. There are no absolute contraindications (i.e., $C=0$ and $E \\in \\{0,1\\}$).\n$3$. If a patient has no absolute contraindications but is not a candidate for immediate resection, they may be a candidate for \"Conversion chemotherapy\". The goal of this therapy is to convert the patient to a resectable state. This typically applies to patients with initially anatomically unresectable disease ($R=0$) who might respond to chemotherapy. This pathway is appropriate only if curative-intent surgery remains a possibility, meaning $C=0$ and $E \\in \\{0,1\\}$.\n\nBased on this logic, we will determine the correct triage for each representative patient.\n\n**Patient 1: $(R=1, F=0.28, H=0, E=0, C=0)$**\n$1$. Check for palliative contraindications: $C=1$ is false. $E=2$ is false. The patient is a candidate for curative-intent therapy.\n$2$. Check for immediate resectability:\n    a. Is the disease anatomically resectable? Yes, $R=1$.\n    b. Is the FLR adequate? The minimal FLR for a normal liver ($H=0$) is $f(0)=0.20$. The patient's expected FLR is $F=0.28$. Since $0.28 \\ge 0.20$, the FLR is adequate.\n    c. Are there other contraindications? No, $C=0$ and $E=0$.\nAll conditions for immediate resection are met.\n**Correct Triage for Patient 1: Resection**\n\n**Patient 2: $(R=0, F=0.22, H=1, E=0, C=0)$**\n$1$. Check for palliative contraindications: $C=1$ is false. $E=2$ is false. The patient is a candidate for curative-intent therapy.\n$2$. Check for immediate resectability: Is the disease anatomically resectable? No, $R=0$. The patient is not a candidate for immediate resection.\n$3$. Check for conversion therapy candidacy: The patient has no absolute contraindications ($C=0$, $E=0$). The reason for non-resectability is the current tumor anatomy ($R=0$), which is the classic indication for conversion chemotherapy. The goal is to shrink the tumors to make them resectable. (Note: The FLR is also inadequate, as $F=0.22 < f(1)=0.30$, further precluding resection, but the primary barrier stated is $R=0$).\n**Correct Triage for Patient 2: Conversion chemotherapy**\n\n**Patient 3: $(E=2, C=1)$**\n$1$. Check for palliative contraindications:\n    a. Is operative risk prohibitive? Yes, $C=1$.\n    b. Is there unresectable extrahepatic disease? Yes, $E=2$.\nThe presence of either one of these factors, and in this case both, makes the patient a candidate for palliation only. Curative-intent hepatectomy is contraindicated.\n**Correct Triage for Patient 3: Palliation**\n\nWith the correct triage for each patient established (Patient 1: Resection, Patient 2: Conversion chemotherapy, Patient 3: Palliation), we now evaluate each proposed algorithm.\n\n**A. If $C=1$ or $E=2$, output “Palliation.” Else, if $R=1$ and $F \\ge f(H)$, output “Resection.” Else, if $R=0$ and $E \\in \\{0,1\\}$, output “Conversion chemotherapy.” Else, output “Palliation.”**\n\n- **Patient 1 $(R=1, F=0.28, H=0, E=0, C=0)$**:\n  - The first condition ($C=1$ or $E=2$) is false.\n  - The second condition ($R=1$ and $F \\ge f(H)$) is true, since $R=1$ and $0.28 \\ge f(0)=0.20$. The algorithm outputs “Resection”. This is correct.\n- **Patient 2 $(R=0, F=0.22, H=1, E=0, C=0)$**:\n  - The first condition ($C=1$ or $E=2$) is false.\n  - The second condition ($R=1$ and $F \\ge f(H)$) is false, since $R=0$.\n  - The third condition ($R=0$ and $E \\in \\{0,1\\}$) is true, since $R=0$ and $E=0$. The algorithm outputs “Conversion chemotherapy”. This is correct.\n- **Patient 3 $(E=2, C=1)$**:\n  - The first condition ($C=1$ or $E=2$) is true. The algorithm outputs “Palliation”. This is correct.\n\nThis algorithm correctly triages all three patients. Furthermore, its logical structure is highly consistent with the established principles. It first screens for absolute contraindications, then identifies ideal resection candidates, and then identifies classic conversion candidates. This hierarchical logic is clinically sound.\nVerdict: **Correct**\n\n**B. If $E \\ge 1$, output “Palliation.” Else, if $R=1$ and $F \\ge 0.20$, output “Resection.” Else, output “Conversion chemotherapy.”**\n\n- **Patient 1 $(R=1, F=0.28, H=0, E=0, C=0)$**:\n  - The first condition ($E \\ge 1$) is false.\n  - The second condition ($R=1$ and $F \\ge 0.20$) is true. The algorithm outputs “Resection”. This is correct.\n- **Patient 2 $(R=0, F=0.22, H=1, E=0, C=0)$**:\n  - The first condition ($E \\ge 1$) is false.\n  - The second condition ($R=1$ and $F \\ge 0.20$) is false, since $R=0$.\n  - The else clause outputs “Conversion chemotherapy”. This is correct.\n- **Patient 3 $(E=2, C=1)$**:\n  - The first condition ($E \\ge 1$) is true, since $E=2$. The algorithm outputs “Palliation”. This is correct.\n\nAlthough this algorithm correctly triages the three patients, its logic fundamentally violates the stated principles in several ways:\n$1$. The rule \"If $E \\ge 1$, output 'Palliation'\" is incorrect. The principles explicitly state that limited, resectable extrahepatic disease ($E=1$) does not preclude curative intent. This algorithm would wrongly palliate such patients.\n$2$. It completely ignores operative risk ($C$). A patient with prohibitive risk ($C=1$) but no extrahepatic disease ($E=0$) would not be palliated and could be incorrectly assigned to conversion chemotherapy or resection.\n$3$. The FLR threshold is hardcoded to $0.20$ and ignores the liver parenchymal status $H$. It would wrongly approve resection for a patient with cirrhosis ($H=2$) and an FLR of $F=0.25$, where the required minimum is $f(2)=0.40$.\nThis algorithm is inconsistent with the principles.\nVerdict: **Incorrect**\n\n**C. If $R=1$, output “Resection” regardless of $F$, $H$, $E$, or $C$. Else, if $F \\ge 0.15$, output “Conversion chemotherapy.” Else, output “Palliation.”**\n\n- **Patient 3 $(E=2, C=1)$**: Let's assume $R=0$ and $F=0.25$ for this patient to test the logic.\n  - The first condition ($R=1$) is false.\n  - The second condition ($F \\ge 0.15$) is true ($0.25 \\ge 0.15$). The algorithm outputs “Conversion chemotherapy”. This is incorrect. Patient $3$ has absolute contraindications to curative-intent therapy ($C=1$ and $E=2$) and must be triaged to \"Palliation\".\nThis algorithm fails for Patient $3$. It has other severe flaws, such as ignoring all contraindications ($C, E, F$) if $R=1$, and using a dangerously low, hardcoded FLR threshold of $0.15$.\nVerdict: **Incorrect**\n\n**D. If disease is bilobar, output “Conversion chemotherapy” regardless of $R$, $F$, $H$, $E$, or $C$. Else, if $R=1$ and $F \\ge f(H)$ and $C=0$ and $E=0$, output “Resection.” Else, output “Palliation.”**\n\n- **Patient 1 $(R=1, F=0.28, H=0, E=0, C=0)$**: The patient has \"bilobar\" disease.\n  - The first condition (\"disease is bilobar\") is true. The algorithm outputs “Conversion chemotherapy”. This is incorrect. Patient $1$ is an ideal candidate for immediate (staged) resection. This rule is a clinical oversimplification that contradicts the premises of the problem, where a plan for resection of bilobar disease is already established.\nThis algorithm fails for Patient $1$.\nVerdict: **Incorrect**\n\n**Conclusion**\nOnly Algorithm A correctly triages all three representative patients. More importantly, its logical structure directly maps to the hierarchy of clinical principles provided in the problem statement: it correctly identifies patients for palliation, then patients for immediate resection, and then patients for conversion therapy. The other algorithms either fail to triage the patients correctly or contain logic that is fundamentally inconsistent with the provided principles of modern surgical oncology.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "After identifying a patient as a potential surgical candidate, quantifying their individual risk is crucial for counseling and shared decision-making. This exercise introduces the classic Fong Clinical Risk Score, a simple yet powerful tool for predicting long-term outcomes after liver resection. By applying this score to a clinical vignette, you will practice extracting key prognostic factors from a patient's history to stratify risk, a fundamental skill in surgical oncology .",
            "id": "5100460",
            "problem": "A patient with colorectal adenocarcinoma underwent curative resection of the primary tumor with pathologic nodal positivity (at least one positive lymph node). Surveillance detects liver-only metastatic disease at a disease-free interval of $18$ months from the date of primary resection. Cross-sectional imaging demonstrates $3$ hepatic metastases, with the largest lesion measuring $6.3$ cm in maximal diameter. The preoperative Carcinoembryonic Antigen (CEA) is $310$ ng/mL. There is no extrahepatic disease on staging. \n\nUse the canonical five-criterion Clinical Risk Score (CRS) described by Fong and colleagues for resectable colorectal liver metastases, which assigns $1$ point for each of the following adverse features:\n- Node-positive primary tumor.\n- Disease-free interval from primary resection to detection of liver metastasis less than $12$ months.\n- More than $1$ hepatic metastasis.\n- Largest hepatic metastasis greater than $5$ cm in diameter.\n- Preoperative Carcinoembryonic Antigen (CEA) greater than $200$ ng/mL.\n\nStarting from these definitions, determine the total Fong Clinical Risk Score for this patient by explicitly evaluating each criterion from first principles and summing the points. Then, based on the standard interpretation that scores $0$–$2$ indicate low risk, $3$ indicates intermediate risk, and $4$–$5$ indicate high risk, provide the numerical score. Report only the numerical score as an integer; no rounding is required and no units should be included in the final response.",
            "solution": "The problem requires the calculation of the Fong Clinical Risk Score (CRS) for a patient with resectable colorectal liver metastases. The calculation is based on a set of five predefined clinical criteria. We will proceed by systematically evaluating each criterion against the patient data provided in the problem statement. A score of $1$ point is assigned for each criterion that is met, and a score of $0$ points is assigned otherwise. The total score is the sum of the points for each of the five criteria.\n\nThe parameters provided for the patient are as follows:\n- Primary tumor nodal status: Node-positive.\n- Disease-free interval (DFI): $18$ months.\n- Number of hepatic metastases: $3$.\n- Size of largest hepatic metastasis: $6.3$ cm.\n- Preoperative Carcinoembryonic Antigen (CEA) level: $310$ ng/mL.\n\nThe five criteria for the Fong CRS are:\n$1$. Node-positive primary tumor.\n$2$. Disease-free interval less than $12$ months.\n$3$. More than $1$ hepatic metastasis.\n$4$. Largest hepatic metastasis greater than $5$ cm.\n$5$. Preoperative CEA level greater than $200$ ng/mL.\n\nWe will now evaluate each criterion for the given patient.\n\n**Criterion 1: Nodal Status of the Primary Tumor**\nThe criterion is met if the primary colorectal tumor was node-positive. The problem states the patient had \"pathologic nodal positivity (at least one positive lymph node)\". Therefore, this criterion is met.\nPoints assigned: $1$.\n\n**Criterion 2: Disease-Free Interval (DFI)**\nThe criterion is met if the disease-free interval from primary resection to the detection of liver metastasis is less than $12$ months. The patient's DFI is given as $18$ months. We evaluate the inequality:\n$$ 18 \\text{ months} \\not< 12 \\text{ months} $$\nSince $18$ is not less than $12$, this criterion is not met.\nPoints assigned: $0$.\n\n**Criterion 3: Number of Hepatic Metastases**\nThe criterion is met if there is more than $1$ hepatic metastasis. The patient is described as having $3$ hepatic metastases. We evaluate the condition:\n$$ 3 > 1 $$\nThis inequality is true. Therefore, this criterion is met.\nPoints assigned: $1$.\n\n**Criterion 4: Size of the Largest Metastasis**\nThe criterion is met if the largest hepatic metastasis is greater than $5$ cm in diameter. The patient's largest lesion measures $6.3$ cm. We evaluate the inequality:\n$$ 6.3 \\text{ cm} > 5 \\text{ cm} $$\nThis inequality is true. Therefore, this criterion is met.\nPoints assigned: $1$.\n\n**Criterion 5: Preoperative Carcinoembryonic Antigen (CEA) Level**\nThe criterion is met if the preoperative CEA level is greater than $200$ ng/mL. The patient's preoperative CEA is given as $310$ ng/mL. We evaluate the inequality:\n$$ 310 \\text{ ng/mL} > 200 \\text{ ng/mL} $$\nThis inequality is true. Therefore, this criterion is met.\nPoints assigned: $1$.\n\n**Calculation of the Total Fong Clinical Risk Score**\nTo find the total CRS, we sum the points from each of the five criteria:\n$$ \\text{Total CRS} = (\\text{Points from Criterion 1}) + (\\text{Points from Criterion 2}) + (\\text{Points from Criterion 3}) + (\\text{Points from Criterion 4}) + (\\text{Points from Criterion 5}) $$\n$$ \\text{Total CRS} = 1 + 0 + 1 + 1 + 1 $$\n$$ \\text{Total CRS} = 4 $$\n\nThe total Fong Clinical Risk Score for this patient is $4$. According to the standard interpretation provided, a score of $3$ indicates intermediate risk, and a score of $4$–$5$ indicates high risk. Thus, this patient falls into the high-risk category. The problem, however, asks only for the numerical score.",
            "answer": "$$\\boxed{4}$$"
        },
        {
            "introduction": "Surgical planning for a major hepatectomy goes beyond just removing the tumor; it is critically dependent on ensuring the patient is left with enough functional liver to survive and recover. This problem provides a hands-on opportunity to perform a vital safety calculation—determining the standardized future liver remnant ($s\\!FLR$). Using volumetric data from a CT scan, you will assess the adequacy of the remaining liver and decide whether a pre-operative intervention like portal vein embolization is necessary to ensure a safe resection .",
            "id": "5100454",
            "problem": "A $62$-year-old with colorectal liver metastases has received $8$ cycles of oxaliplatin-based chemotherapy and is planned for a right hepatectomy (removal of segments $5$–$8$), preserving segments $1$–$4$. Computed Tomography (CT) volumetry provides the following segmental liver parenchymal volumes (in $\\mathrm{mL}$): segment $1$: $50$, segment $2$: $120$, segment $3$: $130$, segment $4$: $100$, segment $5$: $250$, segment $6$: $300$, segment $7$: $280$, and segment $8$: $270$. The total measured liver volume is therefore $1500\\,\\mathrm{mL}$. Metastatic tumor volumes are confined to the right hemiliver: segment $5$: $40\\,\\mathrm{mL}$, segment $6$: $30\\,\\mathrm{mL}$, segment $7$: $20\\,\\mathrm{mL}$, segment $8$: $10\\,\\mathrm{mL}$, with no tumor in segments $1$–$4$.\n\nUse the following foundational definitions and facts:\n- The total functional liver volume (TFLV) is the total hepatic volume excluding all tumor volumes, i.e., $$\\mathrm{TFLV} = \\text{Total liver volume} - \\text{Total tumor volume}.$$\n- The future liver remnant (FLR) for a right hepatectomy is the sum of the volumes of segments $1$–$4$ that will remain.\n- The standardized future liver remnant (sFLR) is defined as the ratio of the FLR to the TFLV, i.e., $$s\\!FLR = \\frac{\\mathrm{FLR}}{\\mathrm{TFLV}}.$$\n- For patients with chemotherapy-associated liver injury risk, a widely accepted safety threshold is $s\\!FLR \\geq 0.3$ to proceed without Portal Vein Embolization (PVE). If $s\\!FLR < 0.3$, PVE is indicated to induce hypertrophy of the remnant.\n\nTasks:\n1. Compute the total tumor volume and then compute the total functional liver volume $\\mathrm{TFLV}$.\n2. Compute the future liver remnant $\\mathrm{FLR}$ for the planned right hepatectomy.\n3. Compute $s\\!FLR$.\n4. Decide whether Portal Vein Embolization (PVE) is indicated for this patient under the chemotherapy-associated threshold criterion.\n\nAnswer specification:\n- Report two quantities in this order: the decimal value of $s\\!FLR$ and a binary decision $D$, where $D = 1$ if PVE is indicated and $D = 0$ otherwise.\n- Round $s\\!FLR$ to four significant figures. Do not include any units for either quantity.\n- Express your final answer as a row vector containing the two values.",
            "solution": "We begin from the provided definitions. The total functional liver volume (TFLV) excludes tumor volume. The total liver volume given by Computed Tomography (CT) is $1500\\,\\mathrm{mL}$. Tumors are confined to segments $5$–$8$ with volumes: segment $5$: $40\\,\\mathrm{mL}$, segment $6$: $30\\,\\mathrm{mL}$, segment $7$: $20\\,\\mathrm{mL}$, segment $8$: $10\\,\\mathrm{mL}$.\n\n1. Compute total tumor volume:\n$$\nV_{\\text{tumor}} = 40 + 30 + 20 + 10 = 100 \\ \\mathrm{mL}.\n$$\nThen compute $\\mathrm{TFLV}$ as total liver volume minus tumor volume:\n$$\n\\mathrm{TFLV} = 1500 - 100 = 1400 \\ \\mathrm{mL}.\n$$\n\n2. Compute the future liver remnant (FLR) for a right hepatectomy, which preserves segments $1$–$4$. The segmental volumes are: segment $1$: $50\\,\\mathrm{mL}$, segment $2$: $120\\,\\mathrm{mL}$, segment $3$: $130\\,\\mathrm{mL}$, segment $4$: $100\\,\\mathrm{mL}$. There are no tumors in segments $1$–$4$, so the remnant is fully functional parenchyma. Thus,\n$$\n\\mathrm{FLR} = 50 + 120 + 130 + 100 = 400 \\ \\mathrm{mL}.\n$$\n\n3. Compute the standardized future liver remnant:\n$$\ns\\!FLR = \\frac{\\mathrm{FLR}}{\\mathrm{TFLV}} = \\frac{400}{1400} = \\frac{2}{7}.\n$$\nAs a decimal, \n$$\n\\frac{2}{7} \\approx 0.285714\\ldots\n$$\nRounded to four significant figures, \n$$\ns\\!FLR = 0.2857.\n$$\n\n4. Decision regarding Portal Vein Embolization (PVE): For chemotherapy-associated liver injury, a widely accepted threshold is $s\\!FLR \\geq 0.3$ to proceed without PVE. Here, $s\\!FLR = \\frac{2}{7} \\approx 0.2857 < 0.3$, so PVE is indicated. Define $D = 1$ if PVE is indicated and $D = 0$ otherwise. Therefore, $D = 1$.\n\nWe report the final answer as a row vector in the order specified: $[s\\!FLR, D]$, with $s\\!FLR$ rounded to four significant figures and no units.",
            "answer": "$$\\boxed{\\begin{pmatrix}0.2857 & 1\\end{pmatrix}}$$"
        }
    ]
}